The Administrative Core provides essential infrastructure linking our member core and clinical trials development teams. It provides expert guidance and oversight to SWOG, develops and maintains our Operations Center organizational structure and policies, and supports an up-to-date set of Standard Operating Procedures that cover all aspects of the Network Group's activities. Administrative Core duties include: ? Establishing conditions for, maintaining records of, and monitoring SWOG institutional and individual membership; ? Operationalizing clinical and translational trial proposals and protocols, continuously searching for development process improvements ? Serious Adverse Event collection and monitoring, as well as patient safety reporting ? Quality assurance and onsite auditing ? Developing, conducting, and assessing training programs ? Tracking and adjudicating financial conflicts of interest ? Establishing, maintaining, and monitoring institutional and individual regulatory requirements ? Meetings management ? Group financial management ? Communications ? Publications and presentations management ? Contracting ? Legal support ? Administering tissue banking, including release of specimens ? Interacting with key members of the NCTN and other organizations The Administrative Core works seamlessly with other SWOG components which have different funding (e.g., our Statistical and Data Management Center), and it oversees SWOG interactions with a variety of NCTN and external components.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA180888-06
Application #
9638291
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-04-26
Budget End
2020-02-29
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Li, Daneng; McCall, Linda M; Hahn, Olwen M et al. (2018) Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat 171:325-334
Kyriakopoulos, Christos E; Chen, Yu-Hui; Carducci, Michael A et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36:1080-1087
Grothey, Axel; Sobrero, Alberto F; Shields, Anthony F et al. (2018) Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 378:1177-1188
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
Harshman, Lauren C; Chen, Yu-Hui; Liu, Glenn et al. (2018) Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol 36:376-382
Walter, Roland B; Michaelis, Laura C; Othus, Megan et al. (2018) Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol 93:E49-E52
Henderson, Tara O; Parsons, Susan K; Wroblewski, Kristen E et al. (2018) Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer 124:136-144
Othus, Megan; Estey, Elihu H; Garcia-Manero, Guillermo et al. (2018) Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. Leukemia :

Showing the most recent 10 out of 249 publications